Company: AGIO
Filing Date: 2025-02-13
Form Type: 10-K
Source: 0001439222-25-000009
Chunk: 12

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-02-13
Form: 10-K
Item: Item 16
Chunk 12
---
,994)$(243,138)

See accompanying Notes to Consolidated Financial Statements.

F-6

Agios Pharmaceuticals, Inc.

Consolidated Statements of Stockholders’ Equity

  Common StockAdditionalPaid-InCapitalAccumulatedOtherComprehensiveIncome (Loss)AccumulatedDeficitTreasuryTotalStockholders’Equity(In thousands, except share amounts)SharesAmountSharesAmountBalance at December 31, 202170,550,631 $71 $2,334,348 $(1,198)$(238,760)(16,216,411)$(802,486)$1,291,975 Unrealized loss on available-for-sale securities— — — (11,337)— — — (11,337)Net loss— — — — (231,801)— — (231,801)Stock-based compensation expense— — 49,296 — — — — 49,296 Common stock issued under stock incentive plan and ESPP705,487 — 2,681 — — — — 2,681 Balance at December 31, 202271,256,118 $71 $2,386,325 $(12,535)$(470,561)(16,216,411)$(802,486)$1,100,814 Unrealized gain on available-for-sale securities— — — 12,094 — — — 12,094 Net loss— — — — (352,088)— — (352,088)Stock-based compensation expense— — 44,766 — — — — 44,766 Common stock issued under stock incentive plan and ESPP905,371 1 5,432 — — — — 5,433 Balance at December 31, 202372,161,489 $72 $2,436,523 $(441)$(822,649)(16,216,411)$(802,486)$811,019 Unrealized loss on available-for-sale securities— — — (1,077)— — — (1,077)Net income— — — — 673,725 — — 673,725 Stock-based compensation expense— — 42,847 — —